Pharmaceuticals
WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak
SHANGHAI, Feb. 11, 2020 /PRNewswire/ -- WuXi Biologics is closely monitoring the coronavirus outbreak. Our management team is working vigilantly to execute our Business Continuity Plan to mitigate any potential risk. All three operating sites inChina, namely Wuxi, Shanghai and Suzhou, will resume...
2020-02-12 08:00
6817
111 Partners with Winhealth to Offer "Free Refill + End-to-End Delivery" Services to Patients with Chronic Diseases
SHANGHAI, Feb. 11, 2020 /PRNewswire/ -- As the novel coronavirus epidemic continues to evolve inChina, the country has introduced controls to prevent the spread of the epidemic and reduce the risk of contagion. Among the measures adopted is home quarantine, which has created challenges for patien...
2020-02-12 06:00
7369
Luye Pharma Grants Cipla Medpro Exclusive Distribution and Marketing Rights for Seroquel® and Seroquel XR® in South Africa and Certain Neighbouring Countries
HONG KONG, Feb. 10, 2020 /PRNewswire/ -- Luye Pharma Group has announced that it has entered into an exclusive distribution and marketing service agreement with Cipla Medpro South Africa (Pty) Limited (Cipla Medpro), for Seroquel® and Seroquel XR® in South Africa, Namibia and Botswana. Cipla Medp...
2020-02-11 08:51
1321
Yuyu's First Generic Newmacor's 5-year Cumulative Sales Surpasses 40 Million Capsules
* Lined up all the sold Newmacor capsules end-to-end would reach 1,043km * Future target growth is to reach blockbuster levels and exceed 10 billion KRW SEOUL, South Korea, Feb. 10, 2020 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX: 000220) is celebrating the 5th anniversary of the ...
2020-02-10 22:00
1555
GenScript ProBio Screens anti-2019 nCoV Antibodies in Just 24 Hours
NANJING, China, Feb. 6, 2020 /PRNewswire/ -- On February 4, 4:46 a.m., escorted by public security officers, 8 transgenic mice for fully human antibodies immunized with antigen from 2019 nCoV from Rongchang District,Chongqing were brought by Chongqing Academy of Animal Sciences and Chongqing CAMA...
2020-02-06 22:46
1709
Bridge Biotherapeutics Acquires a New Drug Development Candidate for Back-Eye Diseases
* Signed a collaboration and license agreement for developing back-eye disease treatments with Konkuk University in the Republic of Korea * A total of 10B KRW deal includes 300M KRW of upfront payment SEONGNAM, South Korea, Feb. 5, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical ...
2020-02-05 13:21
1153
Samsung Biologics Reports 64% Jump in FY19 Earnings, Sees Global Expansion in 2020
INCHEON, South Korea, Feb. 4, 2020 /PRNewswire/ -- Samsung Biologics, a pharmaceutical Contract Manufacturing Organization (CMO), recorded high for the fiscal year 2019, reporting 30.9% growth in sales at701.6 billion won, and 64.6% growth in operating profit at91.7 billion won compared to the ...
2020-02-04 13:50
1053
China Jo-Jo Drugstores Steps in to Help Combat the 2019 Novel Coronavirus
HANGZHOU, China, Feb. 3, 2020 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services inChina, today an...
2020-02-04 06:00
7923
CStone successfully hosted the first U.S. R&D Day in New York
* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical development, with a total of 13 on-going registrational trials. * The Company has implemented its pipeline strategy for early-stage candidates and combination therapy. With an established clinical d...
2020-01-24 08:03
2573
TenNor Therapeutics Received FDA Orphan Drug Designation
SUZHOU, China, Jan. 20, 2020 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections. Medical devices such as prosthetic joints, central venous catheters and artificial hear...
2020-01-20 20:50
964
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC
SEONGNAM, South Korea, Jan. 19, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced that the Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) has been cleared ...
2020-01-20 10:44
1218
111, Inc. Featured at 38th Annual JP Morgan Healthcare Conference
SHANGHAI, Jan. 17, 2020 /PRNewswire/ -- Junling Liu, co-founder, Chairman, and Chief Executive Officer of 111, Inc. (NASDAQ: YI) a leading integrated online and offline healthcare platform, gave an address entitled "Driving Transformation inChina's Healthcare and Pharmaceutical Industry" at the 3...
2020-01-17 20:00
7551
China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory
TAIZHOU, China, Jan. 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Ad...
2020-01-16 21:00
6144
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
* First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities * WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer SHANGHAI and LEVERKUSEN, Germany, Jan. 15, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a ...
2020-01-16 10:39
17961
Hanmi Pharmaceutical participated in the 38th J.P. Morgan Healthcare Conference, announces that it is "ready to lead global pharmaceutical market with innovative R&D pipeline"
SEOUL, South Korea, Jan. 15, 2020 /PRNewswire/ -- The company, led by President and CEO Se-chang Kwon and co-representative Jong-soo Woo, participated in the 38th J.P. Morgan Healthcare Conference inSan Francisco during Jan. 13-15, which it presented its vision and major R&D strategies for 2020. ...
2020-01-16 07:30
1512
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
* The 12th global licensing partnership for WuXiBody™ since its launch in August 2018 showcasing the power and versatile applications of WuXiBody™ in multiple therapeutic areas SHANGHAI and BARCELONA, Spain, Jan. 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global o...
2020-01-09 17:10
2632
Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies
SUZHOU, China and SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced the initiation of an investigational study of GC027, the first product candidate developed usingTruUCAR™ to treat relapsed or refr...
2020-01-07 22:00
1049
GPHL's international headquarters settle in Macao, first project during the fifth-term government of Macao SAR
GUANGZHOU, China, Jan. 6, 2020 /PRNewswire/ -- The beginning of 2020 witnessed key projects promoting the cooperation betweenGuangdong and Macao. On January 3 , Guangzhou Pharmaceutical Group (Macau) International Development Co., Ltd. (hereunder referred to as "the company") was established inMac...
2020-01-06 14:39
1332
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
TAIZHOU, China, Jan. 3, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"),(NASDAQ: SXTC) announced today that on December 27, 2019 the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifyi...
2020-01-03 23:30
6794
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC
* China NMPA cleared the IND application of BBT-401 submitted on September 25, 2019 * The Phase I clinical study in China will be initiated in May 2020 SEONGNAM, South Korea, Dec. 26, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KOSDAQ: 288330), a clinical stage biotech company headquart...
2019-12-27 06:30
1759
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 301 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8676
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5434
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4839